Dupilumab improves patient-reported outcomes in patients with chronic rhinosinusitis with nasal polyps and comorbid asthma

J Allergy Clin Immunol Pract. Sep-Oct 2019;7(7):2447-2449.e2. doi: 10.1016/j.jaip.2019.03.023. Epub 2019 Mar 27.
No abstract available

Publication types

  • Letter
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Anti-Allergic Agents / therapeutic use*
  • Antibodies, Monoclonal, Humanized / therapeutic use*
  • Asthma
  • Biomarkers / metabolism
  • Chronic Disease
  • Comorbidity
  • Double-Blind Method
  • Female
  • Humans
  • Inflammation Mediators / metabolism
  • Male
  • Middle Aged
  • Nasal Polyps / diagnosis*
  • Nasal Polyps / epidemiology
  • Patient Reported Outcome Measures
  • Placebos
  • Rhinitis / drug therapy*
  • Rhinitis / epidemiology
  • Sinusitis / drug therapy*
  • Sinusitis / epidemiology

Substances

  • Anti-Allergic Agents
  • Antibodies, Monoclonal, Humanized
  • Biomarkers
  • Inflammation Mediators
  • Placebos
  • dupilumab